Karyn Dyehouse, MD
Medical Oncology · Seneca, SCNPI 1649297094
Payments from drug & device makers
Across 414 payments — averaging $1072.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$389K
- AstraZeneca$38K
- Eli Lilly$11K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$462
- Gilead$455
- plus $4K from 33 others
Across 1 payment — averaging $1228.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 246 | $388,782 |
| AstraZeneca(2 entities) | 23 | $37,732 |
| Eli Lilly | 2 | $11,156 |
| Novartis | 28 | $1,768 |
| E.r. Squibb & Sons, L.L.C. | 13 | $462 |
| Gilead(2 entities) | 11 | $455 |
| Merck | 8 | $393 |
| Bayer | 11 | $255 |
| Incyte Corporation | 5 | $241 |
| Amgen | 8 | $238 |
| Stemline Therapeutics Inc. | 4 | $208 |
| Lilly USA, LLC | 4 | $175 |
| Galvanize Therapeutics, Inc | 1 | $172 |
| Seagen Inc. | 4 | $168 |
| Rigel Pharmaceuticals, Inc. | 3 | $160 |
| Genentech USA, Inc. | 3 | $153 |
| Ipsen Biopharmaceuticals, Inc | 1 | $145 |
| Daiichi Sankyo Inc. | 6 | $144 |
| Sobi, Inc | 3 | $140 |
| Foundation Medicine, Inc. | 2 | $139 |
| Beigene USA, Inc. | 3 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Puma Biotechnology, Inc. | 2 | $108 |
| Sanofi | 1 | $101 |
| Pfizer | 4 | $77 |
| Karyopharm Therapeutics Inc. | 1 | $71 |
| Blueprint Medicines Corporation | 1 | $70 |
| Bristol Myers Squibb | 2 | $50 |
| Novocure Inc. | 1 | $48 |
| Eisai Inc. | 2 | $46 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| Johnson & Johnson | 1 | $40 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| G1 Therapeutics, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $15 |
| Sirtex Medical Inc | 1 | $11 |
How this compares
$444,124 in reported general payments places this provider in the 70th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Seneca
- John KaczmarCharleston$7.7M
- Theodore GourdinCharleston$2.6M
- Gene SaylorsCharleston$1.1M
- Mariam AlexanderCharleston$833K
- Albert LockhartCharleston$821K
- Frank BresciaCharleston$664K
- Toros DincmanCharleston$570K
- Michael LillyCharleston$472K
- Ming YinGeorgetown$436K
- Kevin BeckerCharleston$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.